• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5616
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 213
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 247
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 638
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
0:03:01

Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the COSMIC-0...

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract - Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

Origins:

C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising clinical activity in COSMIC-021 cohort 2 in patients (pts) with UC who had previously received platinum-containing chemotherapy (chemo) (Pal S et al. ASCO 2020. Abstract 5013). C + A outcomes from three more UC cohorts (C3, C4, C5) are given.

Methodology:

Patients with locally advanced/metastatic UC with transitional cell histology and ECOG PS 0 were eligible. Patients in C3 and C4 had no prior therapy and were either ineligible for cisplatin-based chemotherapy (C3) or eligible (C4) (C4). C5 recruited patients who had received one prior ICI but no prior VEGFR-TKI therapy. C 40 mg PO QD and A 1200 mg IV Q3W were given to the patients. CT/MRI scans were performed every six weeks for the first year and every twelve weeks after that. The primary endpoint is the investigator's objective response rate (ORR) following RECIST v1.1. Other outcomes include safety, response time (DOR), PFS, and OS.

Outcomes:

C3 and C4 received thirty points each, while C5 received 31 points. Baseline characteristics for C3, C4, and C5 were as follows: median age, 74 years, 66 years, 68 years; male, 67 percent, 73 percent, 55 percent ; ECOG PS 1, 63 percent, 57 percent, 74 percent ; lung/liver metastasis, 33 percent/17 percent, 40 percent/20 percent, 58 percent/23 percent ; 3 tumor sites, 30 percent, 43 percent, 45 percent ; bladder as primary site, 67 percent, As of November 30, 2021, the median follow-up for C3, C4, and C5 was 27.9, 19.1, and 32.9 months, with 1, 6, and 1 patients on therapy, respectively. C + A has shown clinical benefit across all cohorts (Table). The most common treatment-related adverse events (TRAEs) of any grade across C3, C4, and C5, respectively, were diarrhea (43 percent, 33 percent, 35 percent), nausea (27 percent, 17 percent, 26 percent), fatigue (27 percent, 27 percent, 48 percent), and decreased appetite (33 percent, 27 percent, 39 percent); there were no grade 5 TRAEs.

Observations:

C + A displayed encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced/metastatic UC as first-line systemic therapy in cisplatin-based chemo eligible/ineligible patients and as second- or later-line therapy un patients who had previously received ICI. NCT03170960 is the clinical trial number.

63 Views
1 year Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Urology

Podcast Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
0:03:01
Podcast Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the ...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
11 Views
Annual Meeting
1 year Ago
Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
0:03:01
Sumanta Pal, MD @montypal @cityofhope @cityofhopeoc #ASCO22 #OncoTwitter Results from Cohorts 3, 4, 5 of the COSMIC-0...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
63 Views
Annual Meeting
1 year Ago
Petros Grivas, MD, PhD @SeattleCCA #UrothelialCancer FDA Approves Avelumab (BAVENCIO) as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carci...
0:10:47
Petros Grivas, MD, PhD @SeattleCCA #UrothelialCancer FDA Approves Avelumab (BAVENCIO) as First-Line Maintenance Treat...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
746 Views
Cancer
3 years Ago
Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers - Abstract 5019 and Abstract 5020 - Abstract 5019 - Shilpa Gupta MD - Cleveland Clinic @CleClinicMD #bladder...
0:03:42
Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers - Abstract 5019 and Abstract 5020 - Ab...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
26 Views
Cancer
3 years Ago
Seth Lerner, MD on Technical Aspects to Delivering the Drug in Urothelial Cancer @bcmhouston
0:02:30
Seth Lerner, MD on Technical Aspects to Delivering the Drug in Urothelial Cancer @bcmhouston
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
33 Views
Cancer
3 years Ago
Seth Lerner, MD on Treating Upper Tract Urothelial Cancer and Adverse Event Rates @bcmhouston
0:03:42
Seth Lerner, MD on Treating Upper Tract Urothelial Cancer and Adverse Event Rates @bcmhouston
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
20 Views
Cancer
3 years Ago
Seth Lerner, MD on Option For Treating Upper Tract Urothelial Cancer @bcmhouston
0:07:14
Seth Lerner, MD on Option For Treating Upper Tract Urothelial Cancer @bcmhouston
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
56 Views
Cancer
3 years Ago
JAVELIN Study: How Does This Affect Clinicians?
0:02:56
JAVELIN Study: How Does This Affect Clinicians?
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
71 Views
Cancer
3 years Ago
What happened to patients with progression of disease?
0:04:31
What happened to patients with progression of disease?
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
29 Views
Cancer
3 years Ago
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
0:04:59
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
37 Views
Cancer
3 years Ago
HCRN GU14-182: Randomized Double-Blind Phase II Study Of Maintenance Pembrolizumab VS Placebo After First-Line Chemotherapy In Patients with mUC.
00:05:11
HCRN GU14-182: Randomized Double-Blind Phase II Study Of Maintenance Pembrolizumab VS Placebo After First-Line Chemot...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
44 Views
Annual Meeting
4 years Ago
HCRN GU14-182 Questions: OS Is The Endpoint Needed To See To Impact Practice, Phase 3 Study Will Answer Future Questions
00:01:26
HCRN GU14-182 Questions: OS Is The Endpoint Needed To See To Impact Practice, Phase 3 Study Will Answer Future Questions
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
70 Views
Annual Meeting
4 years Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173